BUZZ-Australia's Lumos Diagnostics hits near 4-week high as co gets fresh funds

Reuters10-03

** Shares of Australia's Lumos Diagnostics rise as much as 16.2% to A$0.043, their highest levels since Sept 6

** Stock posts its biggest intraday pct gain since Sept 25, on track to record its second straight day of gains, if trend holds

** The medical equipment supplier says it has been awarded A$3 mln ($2.06 mln) in funding from Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services' administration

** Funding to support upcoming Lumos' FebriDx CLIA waiver study and the U.S. FDA application

** FebriDx can aid clinicians with appropriate antibiotic use decisions and will hopefully improve antibiotic stewardship - LDX

** Near 6.7 mln shares change hands, vs 30-day average volume of 5.4 mln shares

** Stock has fallen 38.7% this year, as of 0044 GMT

($1 = 1.4535 Australian dollars)

(Reporting by Roshan Thomas in Bengaluru)

((Roshan.Thomas@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment